|
|
|
|
|
||||||||||||
|
|
|
|
|
|
|
|
价值评估 |
盈利(现时/预测)
3.02/4.36
|
企业价值
8.34B
|
资产负债 |
每股账面净值
3.56
|
现金流量 |
现金流量率
0.06
|
损益表 |
收益
829.25M
|
每股收益
6.14
|
同行比较
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
报价延迟最少15分钟:2025/01/12 22:02 EST
同行比较之报价最少15分钟延迟
业务概览
|
|||
Halozyme Therapeutics Inc is a biotechnology company focused on developing and commercializing novel oncology therapies. The company seeks to create therapies focused on human enzymes that alter tumors. Halozyme focuses on developing its proprietary products in therapeutic areas with unmet medical needs, with a focus on oncology, and licensing its technology to biopharmaceutical companies to collaboratively develop products. The company's operations are based in the United States, with minimal long-lived assets located internationally. |